[Use of cyclosporin A after antilymphocyte serum in renal transplantation]

Area of Science:

• Nephrology
• Immunology
• Transplantation Medicine

Background:

• Cyclosporine A is a vital immunosuppressant in organ transplantation.
• Standard treatment protocols often involve early administration of Cyclosporine A, potentially leading to nephrotoxicity.
• Optimizing immunosuppressive strategies is crucial for improving long-term graft survival and patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of a delayed introduction protocol for Cyclosporine A in renal transplantation.
• To compare graft survival rates and renal function between a delayed Cyclosporine A protocol and standard immunosuppressive therapy.
• To assess the potential for reducing Cyclosporine A-associated nephrotoxicity through a sequential treatment approach.

Main Methods:

• A randomized protocol was employed over 18 months involving 31 patients receiving late-introduced Cyclosporine A (month 3) at low dosage (4-6 mg/kg/day) as monotherapy.
• Standard treatment with prednisone, azathioprine, and antilymphocyte serum was administered initially.
• A control group of 27 patients received standard immunosuppressive treatment.
• Graft survival, rejection episodes, renal function (serum creatinine), and nephrotoxicity were monitored and compared between groups.

Main Results:

• The Cyclosporine A group achieved an actuarial graft survival rate of 94% at 12 and 18 months, compared to 68% in the standard treatment group.
• Rejection episodes occurred in 43% of the Cyclosporine A group versus 51% in the standard treatment group.
• Renal function remained stable after Cyclosporine A introduction, with similar mean serum creatinine values at 1 year post-transplantation between groups.
• Acute and chronic nephrotoxicity, a known complication of Cyclosporine A, was managed within this protocol.

Conclusions:

• A sequential immunosuppressive strategy combining antilymphocyte serum with a delayed introduction of low-dose Cyclosporine A yields excellent renal allograft survival rates (94% at 18 months).
• This protocol effectively preserves renal function, mitigating the nephrotoxicity often associated with early Cyclosporine A administration.
• This approach offers a promising alternative for optimizing immunosuppression in renal transplantation, balancing efficacy and safety.